Now dermatologists are increasingly prescribing the drug Rogaine, known generically as minoxidil, in low-dose pills to help ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Penumbra PEN is gaining traction in the U.S. and international markets on strong customer uptake of its Lightning Bolt and Flash lines. Yet, unfavorable currency movements and rising expenses are ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...

RKLB and HIMS Risks: The Fund invests in swap contracts and options ... Additionally, technological advancements are critical for maintaining competitiveness in this sector, but the high cost and ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operations ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a strong buy.

Hims & Hers is shutting down the dermatology business it acquired four years ago, Business Insider has learned. On Friday, the telehealth company discontinued Apostrophe, the direct-to-consumer ...

March 7 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being ...

Shares of Hims & Hers Health (HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its GLP-1 weight-loss drug Wegovy by more than half. The move obliterates ...